Office for Science and Data Policy
Office of the Assistant Secretary for Planning and Evaluation
U.S. Department of Health and Human Services
Intravenous Immunoglobulin (IVIG) Town Hall Meeting
This report was produced under the direction of Amber Jessup, Task Order Officer, Office of the Assistant Secretary for Planning and Evaluation (ASPE), Office of Science and Data Policy, Jim Scanlon, Deputy Assistant Secretary for Planning and Evaluation (Science and Data Policy), Jerry Regier, Principal Deputy/Assistant Secretary for Planning and Evaluation. The findings and conclusions of this report are those of the author(s) and do not necessarily represent the views of ASPE or HHS.
Research Brief (in PDF format - 1 page)
Executive Summary (in PDF format - 4 pages)
We gratefully acknowledge Amber Jessup (ASPE, Project Officer) for her leadership, guidance, and input throughout this study. We also would like to thank Marty McGeein (ASPE), Jim Scanlon (ASPE), Laina Bush (ASPE), Jerry Holmberg (Office of Public Health and Science), Laurie Feinberg (ASPE), Kimberly Neuman (CMS), Mark Weinstein (FDA), and Maureen Knippen (FDA) for their insightful comments and advice.
Many people in the IGIV industry, including manufacturers, distributors, group purchasing organizations, hospitals, home infusion companies, pharmacies, and physicians, provided valuable information for the study. We are grateful to all of them. Finally, we would like to thank those patients who use IGIV for sharing their experiences with us.